Pipeline
Drugging the “Undruggable”
Canonical disease drivers, but have not been drugged
Improved Drugs for Validated Targets
Improved selectivity or drug characteristics vs available therapeutics
Genetic
Diseases
Well-understood biology
Novel
Targets
Leverage the power and scale of academic collaborations to explore novel biology
Our Pipeline
Each disease area and drug program in our pipeline takes us one step closer to transforming preclinical R&D using computational chemistry to discover small molecule drugs more efficiently than traditional approaches to deliver better medicines, faster.
Wholly Owned
Wholly Owned
Contact us to learn more about out-licensing our assets.
Disease Area (Target)
Discovery
Optimization
Preclinical
Immunology (TYK2)
Immunology (RIPK1)
Immunology (RIPK2)
15 Undisclosed (undisclosed)
18 Undisclosed (undisclosed)
Co-Developed
Co-Developed
Learn more about our growing portfolio companies.
Co-Development Partner
Disease Area (Target)
Discovery
Optimization
Preclinical
Oncology (PIM3)
Oncology (SHP2)
Hematology (Factor XII)
Immunology (cGAS)
Academic Collaborations
Academic Collaborations
Learn more about our research partnerships and biopharma partnerships.
Disease Areas
